- Conditions
- Diabetes Mellitus, Type 2, Diabetic Nephropathy, Obesity
- Interventions
- Not listed
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 2,310 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 212
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Kidney Disease, Chronic
- Interventions
- BI 690517, Placebo to BI 690517, Empagliflozin, Placebo to empagliflozin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 714 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 41
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Canyon Country, California + 34 more
- Conditions
- Type 2 Diabetes Mellitus, Chronic Kidney Disease
- Interventions
- Fasiglifam, Placebo, Antihyperglycemic therapy
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 7
- States / cities
- Whittier, California • Westminster, Colorado • Tampa, Florida + 4 more
- Conditions
- Type2diabetes, Diabetic Kidney Disease
- Interventions
- Investigational Product - MIB 626, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Kidney Disease
- Interventions
- Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD
- Drug
- Lead sponsor
- Mineralys Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 44
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Chula Vista, California + 39 more
- Conditions
- Diabetic Kidney Disease, CAKUT, Chronic Kidney Diseases
- Interventions
- Renal Autologous Cell Therapy (REACT)
- Biological
- Lead sponsor
- Prokidney
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Boise, Idaho
- Conditions
- Diabetic Kidney Disease
- Interventions
- TMX-049, Placebo
- Drug
- Lead sponsor
- Teijin America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 55
- States / cities
- Flagstaff, Arizona • Mesa, Arizona • Alhambra, California + 41 more
- Conditions
- Diabetic Nephropathies
- Interventions
- Finerenone (BAY94-8862), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 823 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Chula Vista, California • Los Angeles, California + 11 more
- Conditions
- Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure
- Interventions
- Sotagliflozin, Placebo
- Drug
- Lead sponsor
- Alessandro Doria
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 13
- States / cities
- Stanford, California • Aurora, Colorado • Orlando, Florida + 10 more
- Conditions
- Diabetic Nephropathies
- Interventions
- BI 685509, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 22
- States / cities
- Huntsville, Alabama • La Mesa, California • Los Gatos, California + 19 more
- Conditions
- Type 2 Diabetes Mellitus, Diabetic Kidney Disease, Adolescent Obesity, Pre Diabetes, Kidney Hypoxia, Puberty
- Interventions
- Aminohippurate Sodium Inj 20%, Iohexol Inj 300 MG/ML, Dextran 40
- Drug
- Lead sponsor
- Petter Bjornstad
- Other
- Eligibility
- 8 Years to 14 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Seattle, Washington
- Conditions
- Diabetic Nephropathy
- Interventions
- Sevelamer Carbonate, calcium carbonate
- Drug
- Lead sponsor
- Gary Striker
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Diabetic Kidney Disease, Chronic Kidney Disease
- Interventions
- Renal Autologous Cell Therapy (REACT)
- Biological
- Lead sponsor
- Prokidney
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Meridian, Idaho
- Conditions
- Diabetes, Kidney Disease, Hypertension
- Interventions
- losartan 100 mg orally once daily, spironolactone 25 mg orally once daily, placebo once orally once daily
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Nervous System, Diabetic Kidney Disease, Diabetes Mellitus, Type 2
- Interventions
- Not listed
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Type 1 Diabetes, T1D Heart Failure, Cardio-renal Vascular Function and Failure, Diabetic Chronic Kidney Disease
- Interventions
- Finerenone, Sotagliflozin
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Portland, Oregon
- Conditions
- Type 1 Diabetes, Diabetic Kidney Disease, Cardiovascular Diseases, Endothelial Dysfunction, Insulin Sensitivity
- Interventions
- Metformin Hcl 1000Mg Tab, Aminohippurate Sodium 20 % Injection, Iohexol 300 Mg/mL Injectable Solution, Placebo
- Drug
- Lead sponsor
- Kalie Tommerdahl
- Other
- Eligibility
- 12 Years to 25 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Seattle, Washington
- Conditions
- Chronic Kidney Disease Stages 3-5, Diabetic Kidney Disease, Hypertensive Kidney Disease
- Interventions
- QRX-3
- Drug
- Lead sponsor
- Ebima Clifford Okundaye
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Pasedena, Texas
- Conditions
- Diabetic Kidney Disease, Hyperuricemia, Diabetes, Diabetes Mellitus, Type 2, Type2 Diabetes, Type 2 Diabetes Mellitus, Diabetic Nephropathies, Diabetes Complications
- Interventions
- Pegloticase 8 MG/ML [Krystexxa]
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 25 Years · Male only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Inspiratory Muscle Strength Training (IMST), Sham Training
- Device
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 14 Years to 40 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Diabetic Nephropathy, Endothelial Dysfunction
- Interventions
- flavonoids
- Dietary Supplement
- Lead sponsor
- Texas Tech University Health Sciences Center
- Other
- Eligibility
- 12 Years to 21 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Amarillo, Texas
- Conditions
- Diabetic Nephropathy, Chronic Kidney Disease
- Interventions
- Zemplar (paricalcitol) capsules, Placebo
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 281 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Fountain Valley, California • Yuba City, California + 21 more
- Conditions
- Chronic Kidney Diseases, Diabetic Kidney Disease
- Interventions
- KidneyIntelX
- Diagnostic Test
- Lead sponsor
- Renalytix AI, Inc.
- Industry
- Eligibility
- 23 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetic Kidney Disease, Chronic Kidney Diseases, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3
- Interventions
- KidneyIntelX
- Diagnostic Test
- Lead sponsor
- Renalytix AI, Inc.
- Industry
- Eligibility
- 23 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York